IN-VIVO INTERACTION OF KETOCONAZOLE AND SUCRALFATE IN HEALTHY-VOLUNTEERS

被引:14
作者
CARVER, PL
BERARDI, RR
KNAPP, MJ
RIDER, JM
KAUFFMAN, CA
BRADLEY, SF
ATASSI, M
机构
[1] UNIV MICHIGAN,SCH MED,ANN ARBOR,MI 48105
[2] VET ADM MED CTR,ANN ARBOR,MI 48105
关键词
D O I
10.1128/AAC.38.2.326
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Absorption of ketoconazole is impaired in subjects with an increased gastric pH due to administration of antacids, H2-receptor antagonists, proton pump inhibitors, or the presence of hypochlorhydria. Sucralfate could provide an attractive alternative in patients receiving ketoconazole who require therapy far acid-peptic disorders. Twelve healthy human volunteers were administered a single 400-mg oral dose of ketoconazole in each of three randomized treatment phases. In phase A, ketoconazole was administered orally with 240 ml of water. In phase B, ketoconazole and sucralfate (1.0 g) were administered simultaneously with 240 ml of water. In phase C, ketoconazole was administered with 240 ml of water 2 h after administration of sucralfate (1.0 g) orally with 240 ml of water. A 680-mg oral dose of glutamic acid hydrochloride was administered 10 min prior to and with each dose of ketoconazole, sucralfate, or ketoconazole plus sucralfate. Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration time curve and maximal concentration of ketoconazole in serum (78.12+/-12.20 versus 59.32+/-13.61 mu g h/ml and 12.34+/-3.07 versus 8.92+/-2.57 mu g/ml, respectively; P<0.05). When ketoconazole was administered 2 h after sucralfate, the observed ketoconazole area under the concentration-time curve was not significantly decreased compared with that of ketoconazole alone. The time to maximal concentrations in serum and the ketoconazole elimination rate constant were not significantly different in any of the three treatment phases. In patients receiving concurrent administration of ketoconazole and sucralfate, doses should be separated by at least 2 h.
引用
收藏
页码:326 / 329
页数:4
相关论文
共 33 条
[1]   PHARMACOKINETICS OF KETOCONAZOLE ADMINISTERED INTRAVENOUSLY TO DOGS AND ORALLY AS TABLET AND SOLUTION TO HUMANS AND DOGS [J].
BAXTER, JG ;
BRASS, C ;
SCHENTAG, JJ ;
SLAUGHTER, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (05) :443-447
[2]   INCREASED GASTRIC PH AND THE BIOAVAILABILITY OF FLUCONAZOLE AND KETOCONAZOLE [J].
BLUM, RA ;
DANDREA, DT ;
FLORENTINO, BM ;
WILTON, JH ;
HILLIGOSS, DM ;
GARDNER, MJ ;
HENRY, EB ;
GOLDSTEIN, H ;
SCHENTAG, JJ .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (09) :755-757
[3]  
BORELLA LE, 1979, ARZNEIMITTEL-FORSCH, V29-1, P793
[4]   EFFECT OF PH ON DISINTEGRATION AND DISSOLUTION OF KETOCONAZOLE TABLETS [J].
CARLSON, JA ;
MANN, HJ ;
CANAFAX, DM .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1983, 40 (08) :1334-1336
[5]  
CARVER PL, IN PRESS J CHROMATOG
[6]   PHARMACOKINETICS OF KETOCONAZOLE IN NORMAL SUBJECTS [J].
DANESHMEND, TK ;
WARNOCK, DW ;
TURNER, A ;
ROBERTS, CJC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 8 (04) :299-304
[7]   UPPER GASTROINTESTINAL (GI) PH IN YOUNG, HEALTHY-MEN AND WOMEN [J].
DRESSMAN, JB ;
BERARDI, RR ;
DERMENTZOGLOU, LC ;
RUSSELL, TL ;
SCHMALTZ, SP ;
BARNETT, JL ;
JARVENPAA, KM .
PHARMACEUTICAL RESEARCH, 1990, 7 (07) :756-761
[8]  
FOX JL, 1986, RSTRIP PHARMACOKINET
[9]  
Gibaldi M, 1982, PHARMACOKINETICS, P409
[10]   SUCRALFATE AND GASTRIC BICARBONATE [J].
GUSLANDI, M .
PHARMACOLOGY, 1985, 31 (05) :298-300